Hans-Jonas Meyer1, Andreas Wienke2, Alexey Surov3. 1. Department of Diagnostic and Interventional Radiology, University of Leipzig, Leipzig, Germany. Electronic address: Hans-jonas.meyer@medizin.uni-leipzig.de. 2. Institute of Medical Epidemiology, Biostatistics, and Informatics, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany. 3. Department of Radiology and Nuclear Medicine, University of Magdeburg, Magdeburg, Germany.
Abstract
OBJECTIVE: Low skeletal muscle mass (LSMM) can be assessed by imaging modalities and is associated with several clinically relevant factors in critically ill patients. Our aim was to establish the effect of computed tomography (CT)-defined LSMM on short-term mortality in critically ill patients based on a large patient sample. METHODS: The MedLine library and the Cochrane and SCOPUS databases were screened for associations between CT-defined LSMM and short-term mortality in critically ill patients up to May 2021. The primary endpoint of the systematic review was the odds ratio of sarcopenia on mortality. In total, nine studies were selected as suitable for the analysis and included into the present analysis. RESULTS: The studies included a total of 1563 critically ill patients with different underlying diagnoses. The pooled overall prevalence of LSMM was 50.9%. The pooled odds ratio for the effect of sarcopenia on short-term mortality was 2.78 (95% confidence interval, 2.05-3.75). CONCLUSIONS: CT-defined LSMM is highly prevalent in critically ill patients, has a relevant effect on short-term mortality, and should be included as a relevant prognostic biomarker in clinical routines.
OBJECTIVE: Low skeletal muscle mass (LSMM) can be assessed by imaging modalities and is associated with several clinically relevant factors in critically ill patients. Our aim was to establish the effect of computed tomography (CT)-defined LSMM on short-term mortality in critically ill patients based on a large patient sample. METHODS: The MedLine library and the Cochrane and SCOPUS databases were screened for associations between CT-defined LSMM and short-term mortality in critically ill patients up to May 2021. The primary endpoint of the systematic review was the odds ratio of sarcopenia on mortality. In total, nine studies were selected as suitable for the analysis and included into the present analysis. RESULTS: The studies included a total of 1563 critically ill patients with different underlying diagnoses. The pooled overall prevalence of LSMM was 50.9%. The pooled odds ratio for the effect of sarcopenia on short-term mortality was 2.78 (95% confidence interval, 2.05-3.75). CONCLUSIONS: CT-defined LSMM is highly prevalent in critically ill patients, has a relevant effect on short-term mortality, and should be included as a relevant prognostic biomarker in clinical routines.
Authors: I A Osuna-Padilla; N C Rodríguez-Moguel; S Rodríguez-Llamazares; C E Orsso; C M Prado; M A Ríos-Ayala; O Villanueva-Camacho; A Aguilar-Vargas; L E Pensado-Piedra; F Juárez-Hernández; C M Hernández-Cárdenas Journal: Clin Nutr Date: 2022-03-01 Impact factor: 7.324